A Google search on “diet and eczema” may be more misleading than helpful, warns pediatric dermatologist Sandipan Dhar.

Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

Topical ruxolitinib cream shows promise as a treatment for inflammatory skin conditions, but lacks consistent data, indicating a need for further research into its use across various dermatologic ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the 11 most profitable NASDAQ stocks to buy now. On June 9, Regeneron ...

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth ...

Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve (roflumilast) for atopic ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced new data from its preclinical study of ZL-1503, the Company’s ...

The Canine Atopic Dermatitis Treatment Market size is expected to experience a considerable valuation bump, from USD 1,182.60 million in 2024 to USD 1,620.50 million in 2034. The updated report points ...

These are the first clinical study results for the drug in a large population of patients with darker skin tones ...

EMA’s veterinary medicinal products committee recommends marketing authorization to Elanco’s Zenrelia to treat atopic dermatitis in dogs: Greenfield, Indiana Monday, June 16, ...

US biotech Regeneron Pharmaceuticals (Nasdaq: REGN) and French pharma major Sanofi (Euronext: SAN) on Saturday presented ...

Phase 2 study to evaluate investigational, once-daily ZORYVE .05% in infants as young as 3 months to less than 2 years with atopic dermatitisAtopic dermatitis impacts 9.6 million children in the ...